Seeking to develop a new class of cancer therapy that causes tumours to simply die, using proprietary peptides.

Pronec Ltd is seeking to develop a cancer therapy that causes tumours to simply die, using proprietary peptides. The Company’s approach aims to causes necrosis (cell death) of a wide range of tumour cell lines in culture, without affecting normal cell lines.

  • Product

    Life Sciences SEIS
  • Sector

    Drug discovery
  • Status

    Closed
  • HMRC

    Advanced Assurance